glp-1 stopping The Exit Strategy: Evidence-Based Methods to Keep the Weight Off After Ozempic, Wegovy, and Mounjaro: Pearce, Agnes Karuka: 9781923604612 Books Ever wonder what happens when

CJC-1295 Operates primarily in research peptide and compounding pharmacy contexts

2020;43(suppl 1):S90-102

A 2007 double-blind, multicenter trial (n=102) showed ALC 1,500 mg/day significantly improved tender point count, total myalgic score, depression, and musculoskeletal pain compared to placebo.[9] A 2015 RCT found ALC 1,500 mg/day comparable to duloxetine 60 mg/day for pain and depression.[8] Most notably, a 2023 RCT demonstrated that adding PEA 1,200 mg/day + ALC 2,000 mg/day to ongoing duloxetine + pregabalin therapy produced significantly greater improvements in Widespread Pain Index, FIQR, and FASmod scores.[7] Role in Treatment: ALC can be used as monotherapy or adjunctive therapy in fibromyalgia

The pre-specified secondary outcomes were (1) all cause-mortality and (2) incidence of a cardiovascular composite event outcome that included: first occurrence of acute myocardial infarction, cardiac arrest or ventricular fibrillation, acute stroke, or coronary revascularization, as previously described and validated using validated International Classification of Diseases, 9th Revision, Clinical Modification (ICD-9-CM) and 10th Revision, Clinical Modification (ICD-10-CM) and procedure codes 52,53,54